Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
Details
Serval ID
serval:BIB_872E092C2090
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
Journal
European journal of radiology
ISSN
1872-7727 (Electronic)
ISSN-L
0720-048X
Publication state
Published
Issued date
02/2009
Peer-reviewed
Oui
Volume
69
Number
2
Pages
204-208
Language
english
Notes
Publication types: Clinical Trial ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy).
This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib.
Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion.
The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.
This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib.
Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases. These pseudocysts remained unchanged in size or stable in size on successive CT examinations (stable disease according to RECIST criteria). Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules. These CT changes represented local recurrence consistent with GIST resistance to Imatinib treatment. WHO or RECIST criteria did not provide a reliable evaluation of disease evolution or recurrence. Development of new enhancement of lesions (parietal thickness or nodule) was the only reliable criterion.
The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.
Keywords
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Benzamides, Female, Follow-Up Studies, Gastrointestinal Stromal Tumors/diagnostic imaging, Gastrointestinal Stromal Tumors/drug therapy, Gastrointestinal Stromal Tumors/secondary, Humans, Imatinib Mesylate, Liver Neoplasms/diagnostic imaging, Liver Neoplasms/drug therapy, Liver Neoplasms/secondary, Male, Middle Aged, Peritoneal Neoplasms/diagnostic imaging, Peritoneal Neoplasms/drug therapy, Peritoneal Neoplasms/secondary, Piperazines/therapeutic use, Pyrimidines/therapeutic use, Reproducibility of Results, Sensitivity and Specificity, Tomography, X-Ray Computed/methods, Treatment Outcome
Pubmed
Web of science
Create date
16/09/2016 11:13
Last modification date
12/05/2025 16:17